Temperature check: How is the CSL (ASX:CSL) share price faring today?

How has the CSL (ASX: CSL) share price been faring lately? We take a look at its latest performance, and the broker price targets.

| More on:
A woman looks surprised as she checks an old-fashion thermometer, indicating a change in share price moevement for biotech companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has had a disappointing last couple of weeks, dragged down 9% with the broader ASX market slump in early March.

This comes despite the company posting an impressive set of numbers from its half-year results in February.

Below, we take a closer look at CSL's most recent update and how brokers view the global biotech's shares.

How did CSL perform for the first-half?

In its results, CSL reported that COVID-19 had temporarily impacted CSL Behring's performance during the first half of 2021 while boosting its Seqirus business. Despite the difference, both segments saw an increase in earnings before interest and tax (EBIT) of 24% and 112%, respectively.

This led to a surge of net profit after tax (NPAT) of $1,810 million, a jump of 44% over the prior corresponding period.

The company stated that global demand for its therapies remained strong, particularly with significant growth in seasonal influenza vaccines. The latter is due to the COVID-19 pandemic driving high rates of people getting protected from the flu.

What were the challenges?

While the results themselves were positive, CSL revealed that it continued to face some challenges.

The company advised that plasma collections remained an issue as restrictions on passenger movements affected blood donations through its collection centres.

In the United States, CSL has moved to reach out to donors through targeted marketing initiatives. This includes turning to social media influencers to encourage giving blood, as well as increased monetary incentives.

Collection volumes at the end of last year stood at 80% when compared against December 2019.

In addition, CSL had to re-prioritise some R&D projects, such as halting its efforts to develop a COVID-19 vaccine with the University of Queensland.

It found that during its Phase 1 trial, patients who were undertaking the vaccine candidate were registering as false positives on HIV tests. In light of this, the company decided not to proceed with further phase 2/3 trials.

Broker update

After reporting its first-half results, several brokers rated the company with varying price points.

The Swiss investment firm UBS cut its price target for CSL by 2.7% to $330.00. Morgan Stanley followed suit to also reduce their rating by 2.5% to $276.00, then upgraded in March to an add rating with a $301.10 price target.

According to a note out of Citi, its analysts have upgraded the biotech giant's shares to a buy rating with a $310.00 price target

The most recent broker note came from Macquarie last week, which has initiated a price of $288.00 for the biotech.

At the time of writing, the CSL share price is sitting at $261.81, up 2.33% for today. 

CSL share price review

Over the past 12 months, the CSL share price has lost around 6%, mostly from its year-to-date performance.

The company's shares moved sideways for much of the period before plummeting on its latest results release. It's worth noting that its shares today are priced the same as when they were back in November 2019.

Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »